Reuters logo
BRIEF-Long-Term analysis of phase 3 head-to-head study confirms Kyprolis® (carfilzomib) regimen extends overall survival in patients with relapsed multiple myeloma
August 30, 2017 / 8:32 PM / 4 months ago

BRIEF-Long-Term analysis of phase 3 head-to-head study confirms Kyprolis® (carfilzomib) regimen extends overall survival in patients with relapsed multiple myeloma

Aug 31 (Reuters) - Amgen Inc

* Long-Term analysis of phase 3 head-to-head study confirms Kyprolis® (carfilzomib) regimen extends overall survival in patients with relapsed multiple myeloma

* Amgen Inc - Endeavor study long-term data shows Kyprolis and Dexamethasone reduced risk of death by 24 percent versus Velcade and Dexamethasone​

* Amgen Inc - Patients treated with Kyprolis-based regimen survived 9.0 months longer than patients receiving Velcade and Dexamethasone​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below